More importantly, we present a combination strategy of STING agonists and AKT1 inhibitors that could block the positive feedback loop to maximize the activation of cGAS‐STING signaling in endocrine‐resistant breast cancer cells, overcoming endocrine resistance. The gene discussed is STING1; the disease is breast cancer.